✦ LIBER ✦

Reduced-Dose Melphalan vs. Standard Dose Melphalan for Autologous Stem Cell Transplantation: Is There a Difference in Outcome?

✍ Scribed by I. Maewal; A. Gulbis; R.E. Champlin; M.H. Qazilbash

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term outcome of high-dose melphalan

✍ Perz, J B; Rahemtulla, A; Giles, C; Szydlo, R M; Davis, J; Gopaul, D; Gillmore, 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 142 KB

Timing of High Dose Melphalan (HDM) and

✍ A. Mahindra; B. Bolwell; L. Rybicki; R. Sobecks; B. Pohlman; S. Andresen; M. Ear 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Risk-factors of melphalan/fludarabine do

✍ N. Kroger; J.A. Perez-Simon; H. Myint; H. Klingemann; A. Shimoni; A. Nagler; R. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 59 KB

High-dose idarubicine, busulphan and mel

✍ Meloni, G; Capria, S; Trasarti, S; Ferrazza, G; Micozzi, A; Petrucci, M T; Simon 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 57 KB

Double high-dose therapy for Hodgkin’s d

✍ Stewart, D A; Guo, D; Glück, S; Morris, D; Chaudhry, A; deMetz, C; Klassen, J; B 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 65 KB

Prospective randomised trial of amifosti

✍ Spencer, A; Horvath, N; Gibson, J; Prince, H M; Herrmann, R; Bashford, J; Joske, 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 145 KB